Drugs / NanO2TM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03862430 | Mar 2023 → Jun 2026 overdue | glioblastoma | NuvOx LLC | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-03-17 | NuvOx LLC | Regulatory NuvOx Announces Receipt of IND for Study of NanO2 as Cardioprotectant in Acute Myocardial Infarction nuvoxtherapeutics.com ↗ |
| 2023-08-30 | NuvOx LLC | Results NuvOx Announces Publication of Research Article in Cancer Research Communication nuvoxtherapeutics.com ↗
The data showed increase in overall survival and progression free survival compared to historical control. |
| 2021-09-09 | NuvOx LLC | Results NuvOx Pharma Generates Positive Preclinical Data Showing NanO2TM Boosts Efficacy of Immunotherapy nuvoxtherapeutics.com ↗
NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has generated positive preclinical data showing that its lead drug, NanO2TM, boosts the efficacy of immunotherapy in a mouse model of triple negative breast cancer. |
| 2021-07-29 | NuvOx LLC | Regulatory NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM nuvoxtherapeutics.com ↗
NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO2TM, in ischemic stroke. |
All press releases naming this drug 4 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NanO2TM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03862430 ↗ |
| Route | Intravenous | “NanO2TM administered via intravenous infusion” NCT03862430 ↗ |